Is Alumis Inc. Common Stock (ALMS) overvalued? · rev $2.1M
Alumis Inc. Common Stock (ALMS) is a biotechnology company listed on US.
This page asks whether Alumis Inc. Common Stock (ALMS) looks expensive on cached numbers — not a short thesis.
Latest reported ALMS revenue for 2025-09-30 was $2.1M. Net income was -$150.4M. Revenue was down 22.5% from 2025-06-30 to 2025-09-30. ALMS currently screens at market cap $311.6M.
ALMS currently screens at market cap $311.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALMS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALMS stock page for the full model, not this heading.
Not investment advice.